None
EN
Advancing therapies for rare bone diseases in Montreal
['Desiree Zagbai', '.Wp-Block-Co-Authors-Plus-Coauthors.Is-Layout-Flow', 'Class', 'Wp-Block-Co-Authors-Plus', 'Display Inline', '.Wp-Block-Co-Authors-Plus-Avatar', 'Where Img', 'Height Auto Max-Width', 'Vertical-Align Bottom .Wp-Block-Co-Authors-Plus-Coauthors.Is-Layout-Flow .Wp-Block-Co-Authors-Plus-Avatar', 'Vertical-Align Middle .Wp-Block-Co-Authors-Plus-Avatar Is .Alignleft .Alignright']
CityNews Montreal
A new biopharmaceutical company is devoted to developing therapies for rare bone diseases in Montreal.
“It’s always exciting to look at new diseases and see that you can have an impact,” said Mancini, who is also vice-president at adMare BioInnovations.
“It really changes someone’s life.”Patients living with rare bone disorders have limited treatment options.
The two diseases Ocythera is focusing on are hereditary multiple osteochondromas (HMO) and fibrodysplasia ossificans progressiva (FOP).
Overall, in Quebec, rare diseases can affect up to eight per cent of the population.